These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2787712)

  • 1. Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3 in clinically healthy individuals.
    Hashimoto S; McCombs CC; Michalski JP
    Clin Exp Immunol; 1989 Jun; 76(3):317-23. PubMed ID: 2787712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3: role of interleukin-1.
    Hashimoto S; Michalski JP; Berman MA; McCombs C
    Clin Exp Immunol; 1990 Feb; 79(2):227-32. PubMed ID: 2311300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-B8,DR3 T cell impairment is completely restored by in vitro treatment with interleukin-2.
    Candore G; Colucci AT; Modica MA; Caruso C
    Immunopharmacol Immunotoxicol; 1991; 13(4):551-61. PubMed ID: 1774436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro cytokine production by HLA-B8,DR3 positive subjects.
    Candore G; Cigna D; Gervasi F; Colucci AT; Modica MA; Caruso C
    Autoimmunity; 1994; 18(2):121-32. PubMed ID: 7742473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired lymphocyte responsiveness to phytohaemagglutinin associated with the possession of HLA-B8/DR3.
    Amer A; Singh G; Darke C; Dolby AE
    Tissue Antigens; 1986 Oct; 28(4):193-8. PubMed ID: 3492778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of T lymphocyte activation in HLA-B8, DR3 positive individuals.
    Modica MA; Zambito AM; Candore G; Caruso C
    Immunobiology; 1990 Nov; 181(4-5):257-66. PubMed ID: 2129202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro.
    Candore G; Cigna D; Todaro M; De Maria R; Stassi G; Giordano C; Caruso C
    Hum Immunol; 1995 Apr; 42(4):289-94. PubMed ID: 7558912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-B8,DR3 phenotype and lymphocyte responses to phytohaemagglutinin.
    Modica MA; Cammarata G; Caruso C
    J Immunogenet; 1990; 17(1-2):101-7. PubMed ID: 2212697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased interleukin-2 receptor affinity in normal HLA A1 B8 DR3 subjects.
    Pomier G; Vindimian M; Healy JC; Le Petit JC
    J Immunogenet; 1990 Dec; 17(6):371-7. PubMed ID: 2096181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-B8/DR3 phenotype and the primary immune response.
    Kallenberg CG; Klaassen RJ; Beelen JM; The TH
    Clin Immunol Immunopathol; 1985 Jan; 34(1):135-40. PubMed ID: 3871182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte abnormality associated with HLA-B8 in healthy young adults.
    McCombs CC; Michalski JP
    J Exp Med; 1982 Sep; 156(3):936-41. PubMed ID: 6980966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro impairment of interleukin-5 production in HLA-B8, DR3-positive individuals implications for immunoglobulin A synthesis dysfunction.
    Lio D; D'Anna C; Gervasi F; Cigna D; Modica MA; Candore G; Caruso C
    Hum Immunol; 1995 Nov; 44(3):170-4. PubMed ID: 8666553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin genes, HLA-B8/DR3, and immune responsiveness to primary immunogen and mitogens in normal subjects.
    Kallenberg CG; Klaassen RJ; Westra J; Beelen JM; Ockhuizen T
    Clin Immunol Immunopathol; 1988 Jun; 47(3):333-42. PubMed ID: 3259481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer and lymphokine-activated killer activity in HLA-B8,DR3-positive subjects.
    Caruso C; Candore G; Colucci AT; Cigna D; Modica MA; Tantillo G; Salerno A
    Hum Immunol; 1993 Nov; 38(3):226-30. PubMed ID: 8106282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals.
    Stassi G; Todaro M; De Maria R; Candore G; Cigna D; Caruso C; Galluzzo A; Giordano C
    Hum Immunol; 1997 Jun; 55(1):39-45. PubMed ID: 9328788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble interleukin-2 receptor secretion defect in vitro in HLA-B8, DR3 positive subjects.
    Modica MA; di Lorenzo G; Galluzzo A; Giordano C; Portelli MR; Candore G; Caruso C
    Autoimmunity; 1990; 7(2-3):87-96. PubMed ID: 2104185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of cytokine patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity.
    Lio D; Candore G; Romano GC; D'Anna C; Gervasi F; Di Lorenzo G; Modica MA; Potestio M; Caruso C
    Cytokines Cell Mol Ther; 1997 Dec; 3(4):217-24. PubMed ID: 9740350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-B8,DR3 haplotype affects lymphocyte blood levels.
    Caruso C; Bongiardina C; Candore G; Cigna D; Romano GC; Colucci AT; Di Lorenzo G; Gervasi F; Manno M; Potestio M; Tantillo G
    Immunol Invest; 1997 Apr; 26(3):333-40. PubMed ID: 9129986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype.
    Chengappa KN; Ganguli R; Yang ZW; Shurin G; Brar JS; Rabin BS
    Biol Psychiatry; 1995 Apr; 37(8):546-9. PubMed ID: 7619978
    [No Abstract]   [Full Text] [Related]  

  • 20. [HLA typing and insulin antibody production in insulin-dependent diabetics].
    Bruni B; Barolo P; Gadaleta G; Gamba Ansaldi S; Grassi G; Zerbinati A; Molinatti M; Salvetti E
    Ann Osp Maria Vittoria Torino; 1984; 27(7-12):185-213. PubMed ID: 6443704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.